IMP321, also known as eftilagimod alpha, is a soluble LAG-3Ig fusion protein that functions as a antigen presenting cell (APC) activator. It’s being developed to enhance the immune response against tumors by stimulating dendritic cells (DCs) through MHC class II molecules. This leads to the activation of CD8+ T cells, which are crucial for fighting cancer. IMP321 is being investigated for its potential in various cancers, including metastatic breast cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma. The directory classifies it as a clinical API with a peptide source/manufacturing origin. Other names for this substance include Eftilagimod alpha and Efti. Its PubChem CID is 72941955.
Imp-321
| CAS No | 928150-91-8 |
|---|---|
| Molecular Formula | C56H78N18O14S |
| Molecular Weight | 1259.4 g/mol |
| Synonyms | (4R)-4-[[(2R)-6-amino-2-[[(2R)-2-[[4-(aminocarbamothioylamino)benzoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-5-[[(2R)-1-amino-6-[bis[2-[[4-[2-(1H-imidazol-5-yl)ethylamino]-4-oxobutanoyl]amino]acetyl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
IMP321, also known as eftilagimod alpha, is a soluble LAG-3Ig fusion protein that functions as a antigen presenting cell (APC) activator. It's being developed to enhance the immune response against tumors by stimulating dendritic cells (DCs) through MHC class II molecules.
The listed CAS number is 928150-91-8.
The listed molecular formula is C56H78N18O14S.
The listed molecular weight is 1259.4 g/mol.
(4R)-4-[[(2R)-6-amino-2-[[(2R)-2-[[4-(aminocarbamothioylamino)benzoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-5-[[(2R)-1-amino-6-[bis[2-[[4-[2-(1H-imidazol-5-yl)ethylamino]-4-oxobutanoyl]amino]acetyl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid.
The source lists Eftilagimod alpha and Efti.